Mangalam Drugs & Organics (NSE:MANGALAM) Growth Rank: 2 (As of Aug. 31, 2026) — 50% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:MANGALAM Mangalam Drugs & Organics Ltd NSE:MANGALAM
44 GF Score
Price ₹31.94
GF Value ₹61.97
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Mangalam Drugs & Organics Growth Rank?

Mangalam Drugs & Organics NSE:MANGALAM -0.65% 44 Growth Rank is 2 as of Aug. 31, 2026, which is 50% below its 10-year median of 4.00. GuruFocus rates NSE:MANGALAM with a GF Score™ of 44/100 and a GF Value™ of ₹61.97 (Possible Value Trap). The stock has 4 warning signs investors should review.

Mangalam Drugs & Organics has the Growth Rank of 2.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Mangalam Drugs & Organics Growth Rank Related Terms

NSE:MANGALAM vs ZTS: Growth Rank Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Mangalam Drugs & Organics's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mangalam Drugs & Organics Growth Rank vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mangalam Drugs & Organics's Growth Rank distribution charts can be found below:

* The bar in red indicates where Mangalam Drugs & Organics's Growth Rank falls into.


NSE:MANGALAM
44GF Score
Mangalam Drugs & Organics Ltd NSE:MANGALAM
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 2 mean?
Mangalam Drugs & Organics (NSE:MANGALAM) has a Growth Rank of 2 as of Aug. 31, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Mangalam Drugs & Organics and its competitors. This is 50% below median its historical median of 4.00. Over the past decade, Mangalam Drugs & Organics' Growth Rank has ranged from 1.00 to 6.00.
Is Mangalam Drugs & Organics' Growth Rank too high?
Mangalam Drugs & Organics' current Growth Rank of 2 is 50% below median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 6.00. Overall, Mangalam Drugs & Organics has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mangalam Drugs & Organics' Growth Rank compare to ZTS?
Mangalam Drugs & Organics' Growth Rank of 2 can be compared against companies in the Drug Manufacturers industry. Historically, Mangalam Drugs & Organics' own Growth Rank has ranged from 1.00 to 6.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Drug Manufacturers company?
A good Growth Rank depends on the Drug Manufacturers industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Mangalam Drugs & Organics and its competitors. Mangalam Drugs & Organics's current Growth Rank is 2, which is 50% below median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mangalam Drugs & Organics stock overvalued right now?
Based on GuruFocus' analysis, Mangalam Drugs & Organics (NSE:MANGALAM) is currently considered Possible Value Trap. The stock's GF Value™ is ₹61.97, compared to a current price of ₹31.94 — trading 48.5% below its estimated fair value. The current Growth Rank is 2, which is 50% below median its 10-year median of 4.00. Mangalam Drugs & Organics' overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Mangalam Drugs & Organics (NSE:MANGALAM), the current Growth Rank is 2 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mangalam Drugs & Organics (NSE:MANGALAM) Overvalued in 2026?

Based on GuruFocus' analysis, Mangalam Drugs & Organics stock appears to be undervalued. The current stock price of ₹31.94 is trading 48.5% below its estimated GF Value™ of ₹61.97. GuruFocus considers Mangalam Drugs & Organics to be Possible Value Trap.

Key valuation signals for NSE:MANGALAM:

  • Growth Rank: 2 (50% below median its 10-year median of 4.00)
  • GF Value™: ₹61.97 vs. price of ₹31.94 (48.5% below fair value)
  • GF Score™: 44/100 with 4 warning signs

No single metric tells the full story. See the NSE:MANGALAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mangalam Drugs & Organics Business Description

Other Exchanges 532637:India
Address P. D'Mello Road, Rupam Building, 3rd Floor, No. 239, Near General Post Office, Mumbai, MH, IND, 400001
Mangalam Drugs & Organics Ltd commenced its manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates. The company is engaged in the manufacture and sale of APIs for various therapeutic segments, including anti-malaria, anti-retroviral, and anti-hypertensive. It is approved by the Bill Clinton Foundation. The company is actively producing Pyronaridine Tetraphosphate, a new API used in antimalarial treatments. The company has received prequalification from the World Health Organization (WHO) for both micronized and non-micronized forms of Pyronaridine Phosphate.
44GF Score

Get the complete analysis for NSE:MANGALAM

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹31.94
Price
₹61.97
GF Value